申请人:Lilly Industries Limited
公开号:US04230709A1
公开(公告)日:1980-10-28
Pharmaceutical formulations are described, which comprise a hydantoin of formula (I): ##STR1## wherein R.sup.1 is C.sub.1-4 alkyl, R.sup.2 is hydrogen or C.sub.1-4 alkyl; or R.sup.1 and R.sup.2 taken together either represent a C.sub.4-6 alkylene group or a group of formula: ##STR2## where R.sup.5 and R.sup.6 independently represent hydrogen or C.sub.1-4 alkyl; R.sup.3 is C.sub.1-6 alkyl or benzyl; R.sup.4 is hydrogen or C.sub.1-6 alkyl; provided that R.sup.2 and R.sup.4 cannot both be hydrogen; or R.sup.1 and R.sup.4 taken together represent a C.sub.2-4 alkylene group; associated with a pharmaceutically-acceptable carrier therefor. The compounds, some of which are novel, are useful in the treatment of immediate hypersensitivity diseases such as asthma.
描述了一种包含式(I)的咪唑啉的制药配方:其中R.sup.1是C.sub.1-4烷基,R.sup.2是氢或C.sub.1-4烷基;或者R.sup.1和R.sup.2一起表示C.sub.4-6烷基烃基或者公式的基团:其中R.sup.5和R.sup.6独立地表示氢或C.sub.1-4烷基;R.sup.3是C.sub.1-6烷基或苄基;R.sup.4是氢或C.sub.1-6烷基;条件是R.sup.2和R.sup.4不能同时为氢;或者R.sup.1和R.sup.4一起表示C.sub.2-4烷基烃基;与其相配的药用载体相关联。这些化合物中的一些是新颖的,可用于治疗哮喘等即时过敏性疾病。